Novo Nordisk rebrands as 'Novo' to compete with Eli Lilly in obesity market
The Danish drugmaker drops 'Nordisk' from its name to signal a more competitive future while trailing rival Eli Lilly in the weight-loss sector.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
First reported by News Feed, 42 min ahead of the next publisher · who breaks stories first
This story has stopped developing; this page is its permanent record. More from that day
The story so far
7 publishers have covered this in 10 articles since 14 Sept 2026. News Feed published first, on 14 September at 08:16 UTC; STAT followed 42 min later. The most recent article, from Inc., appeared on 16 September at 22:24 UTC.
Outlets reporting it: News Feed (major outlet), CNBC (major outlet), STAT, South China Morning Post, Quartz, MarketWatch, Inc..
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
- News FeedNovo ditches Nordisk from name as drugmaker attempts revival
- STATSTAT+: What’s in a name? Novo looks to a rebrand
- South China Morning PostOzempic-maker Novo Nordisk slims down to ‘Novo’
- QuartzNovo Nordisk wird sich als "Novo" umbenennen, um Eli Lilly im Marktanteil für Adipositas entgegenzutreten.
- QuartzNovo Nordisk is rebranding as 'Novo' to fight Eli Lilly for obesity market share
- STATSTAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more
- MarketWatchNovo drops ‘Nordisk’ in corporate refresh to take on Lilly in the weight-loss wars
- CNBCNovo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy
- QuartzNovo Nordisk wird als 'Novo' umbenannt, um Eli Lilly im Kampf um Marktanteile im Bereich Adipositas herauszufordern.
- Inc.Novo Nordisk Cut Patient Documentation From Months to Minutes. Now It Wants Claude to Speed Drug Research
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy CNBC ·
- Novo ditches Nordisk from name as drugmaker attempts revival News Feed ·
- Novo Nordisk Cut Patient Documentation From Months to Minutes. Now It Wants Claude to Speed Drug Research Inc.
- Novo Nordisk wird als 'Novo' umbenannt, um Eli Lilly im Kampf um Marktanteile im Bereich Adipositas herauszufordern. Quartz
- Novo drops ‘Nordisk’ in corporate refresh to take on Lilly in the weight-loss wars MarketWatch
- STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more STAT
Show 4 more sources
- Novo Nordisk wird sich als "Novo" umbenennen, um Eli Lilly im Marktanteil für Adipositas entgegenzutreten. Quartz
- Novo Nordisk is rebranding as 'Novo' to fight Eli Lilly for obesity market share Quartz
- Ozempic-maker Novo Nordisk slims down to ‘Novo’ South China Morning Post
- STAT+: What’s in a name? Novo looks to a rebrand STAT
In this story
- Novo Nordisk
- Eli Lilly